Published in Cancer Weekly, April 14th, 1997
Although scientific advances have been made in several cancer treatment areas, the survival of patients with pancreatic cancer of exocrine origin has changed relatively little in the past 30 years. Unfortunately, 90 percent of pancreatic cancer patients are diagnosed as unresectable with metastases to regional lymph nodes, the liver and peritoneal surfaces. Even in patients who are surgically resectable, median survival does not exceed two years, and the five year survival rate is a dismal 15-25 percent. New and innovative...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.